Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose

Completed · Phase 3

Conditions studied: Meningococcal Infection

In brief

This study is to assess the longevity of immune response in adolescents for approximately 48 months after receipt of a primary series of bivalent rLP2086 vaccination, which is then followed by a booster dose and an assessment of immune response for 12 or 26 months post booster vaccination.

Key facts

Study ID
NCT01543087
Run by
Pfizer
People needed
698
Starts
2012-09-07
Expected to finish
2018-01-05
Last updated by the study team
2020-03-27

Who can join

Age: 10 and older, up to 18. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.